The France-based biotechnology company Novasep has announced Nadege Laborde as the new president of its industrial biotech business unit. 6 December 2013
The UK’s ‘Golden Triangle’ of biotech innovation can compete on the world stage, AstraZeneca (LSE: AZN) chief executive Pascal Soriot told the Financial Times Global Pharmaceutical & Biotechnology Conference in London today. 3 December 2013
Japan’s largest drugmaker, Takeda Pharmaceutical, says that Christophe Weber has been approved at the company's board of directors meeting to become chief operating officer and candidate as the next chief executive of the company. 29 November 2013
US-based MedImmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca (LSE: AZN), has named Yong-Jun Liu as the company’s new head of research. 20 November 2013
UK-based biotech company Immunocore has appointed Jonathan Knowles as the new executive chairman of the board of directors with immediate effect. 20 November 2013
UK-based developer of inhaled therapies Vectura Group (LSE: VEC) has announced the appointment of Bruno Angelici to the board as an independent non-executive director and non-executive chairman designate. 20 November 2013
US-headquartered biotech company AmpliPhi BioSciences (OTCBB: APHB) has appointed Baxter Phillips III to the newly created position of vice president, corporate strategy and business development. 20 November 2013
To support its ongoing success as a BioPharma leader, US drug major Bristol-Myers Squibb says it is evolving its business model, creating a global integrated commercial organization and expanding the scope of its finance organization, and has announced a series of related changes within its senior management team. 14 November 2013
AstraZeneca today announced that Marc Dunoyer has been appointed chief financial officer and will join the company board as an executive director, effective tomorrow. 31 October 2013
Israel-based Teva Pharmaceutical Industries, say that, despite its recent denials of a rift with its chief executive, its board of directors has agreed with Jeremy Levin that he will step down as president and CEO, just 18 months after assuming the positions at Teva, the world’s largest generics firm. 30 October 2013
Merck KGaA announced today that Gerhard Schmitz will join the pharmaceutical, chemical and life science company as the new Head of Global Accounting from November 1. 30 October 2013
Mergers and acquisitions are common – 111 M&As took place in the UK in the second quarter of 2013 alone – yet there is no ‘one-size fits all’ formula to ensure smooth transitions, writes Chris Molloy, chief executive at RSA, executive search and interim management experts to the life sciences industry. 22 October 2013
Ablynx has announced that Peter Fellner, Bo Jesper Hansen and William Jenkins will be proposed for nomination as Independent Non-Executive Directors at the company's forthcoming extraordinary meeting of its shareholders to be held on November 7. 8 October 2013
US drugmaker Forest Laboratories (NYSE: FRX) saw its shares rise 2.5% to $44.50 yesterday (September 10), after it announced the appointment of Brenton Saunders as its chief executive officer and president, effective from October 1. 11 September 2013
With a clear passion for helping patients and a self-confessed need to know everything that is happening "on the shopfloor," Jan-Anders Karlsson is arguably a pharma chief executive like no other, writes TPL's Sophie Flowers after an interview with the man himself. 22 July 2013
US biotech Paragon Therapeutics yesterday revealed that biotech industry veteran Susanna High has been appointed as chief executive (CEO). In this newly-created role, Ms High will lead the team’s continued efforts to propel the development of a pipeline of transformative therapies and accelerate their potential impact. 22 November 2024
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
New York-based Mind Medicine, a company developing MM120, a form of LSD (lysergide d-tartrate), for mental health conditions, has announced the appointment of Gregg Pratt, as chief regulatory and quality assurance officer. 19 November 2024
Belgian biotech start-up ExeVir Bio says it has appointed Michael Garrett as its new chief executive (CEO), effective 1 December 2024. 18 November 2024
ALX Oncology Holdings, a Californian immuno-oncology company, has announced the appointment of Alan Sandler as chief medical officer (CMO). 14 November 2024
US ophthalmology specialist Ocular Therapeutix announced that Namrata Saroj has joined the Company on a full-time basis as chief business officer (CBO). Dr Saroj previously served as development strategy consultant to Ocular since February 2024. 14 November 2024
VarmX, a Dutch biotech developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has appointed industry veteran John Glasspool (pictured, above) as chief executive. 12 November 2024
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024
Fennec Pharmaceuticals has announced the addition of three new executives to bolster its leadership team as the company prepares for expanded commercial operations. 28 October 2024